# A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.

> **NCT07180771** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 44 (estimated)

## Conditions studied

- Peripheral T Cell Lymphoma

## Interventions

- **DRUG:** BR101801

## Key facts

- **NCT ID:** NCT07180771
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07180771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07180771, "A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07180771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*